Erratum: Blood pressure changes after intravitreal bevacizumab in patients grouped by ocular pathology (Eye (2010) 24 (320-1324)DOI:10.1038/eye.2010.22);Blood pressure changes after intravitreal bevacizumab in patients grouped by ocular pathology

Eye

Volumn 24, Issue 8, 2010, Pages 1320-1324

  Chung, Y R ^a   Lee, K ^b   Cho, E H ^a   Lew, H M ^a  

^a Ajou University School of Medicine   (South Korea)

^b Gunsan Medical Center   (South Korea)

Author keywords

Avastin; bevacizumab; blood pressure; ocular pathology

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CENTRAL SEROUS RETINOPATHY; COMPARATIVE STUDY; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; EYE DISEASE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINA BLOOD VESSEL OCCLUSION; RETINA MACULA EDEMA; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; SYSTOLIC BLOOD PRESSURE;

EID: 77955640616     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2010.143     Document Type: Erratum

References (19)

1. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema. Ophthalmology 2007; 114: 743-750.
2. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. Ophthalmology 2005; 112: 1035-1047.
3. Rich RM, Resenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn Jr HW et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006; 26: 495-511.
4. Gündü z K, Bakri SJ. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion. Eye 2008; 22: 1168-1171.
5. Tolentino MJ, Miller LW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K et al. Intravitreal injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 2006; 103: 1820-1828.
6. Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 1996; 114: 964-970. (Pubitemid 26271462)
7. Adamis AP, Miller JW, Bernal MT, DAmico DJ, Folkman J, Yeo TK et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445-450.
8. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487.
9. Peer J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995; 72: 638-645.
10. Lopez PF, Sippy BD, Lambert M, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degenerationrelated membranes. Invest Ophthalmol Vis Sci 1996; 37: 855-868.
11. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996; 37: 1929-1934.
12. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008; 246: 81-87.
13. Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90: 1344-1349.
14. Mourad JJ, des Guetz G, Dabbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008; 19: 927-934.
15. Kernt M, Neubauer AS, Kampik A. Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand 2007; 85: 119-120. (Pubitemid 46140172)
16. Lee K, Yang H, Lim H, Lew HM. A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection. Retina 2009; 29: 1409-1417.
17. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114: 855-859.
18. Ziemssen F, Zhu Q, Peters S, Grisanti S, El Wardani M, Szurman P et al. Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study. Int Ophthalmol 2009; 29: 213-224.
19. Ceyhan M, Gunaydin S, Yorgancioglu C, Zorlutuna Y, Uluoglu C, Zengil H. Comparison of circadian rhythm characteristics of blood pressure and heart rate in patients before and after elective coronary artery bypass surgery. Chronobiol Int 2003; 20: 337-349.